Disease relevance of C1QL3

• Four lambda antibodies, all cross-reactive with the structurally related antigen Escherichia coli K100 PS, use V lambda VII segments which are 96-98% homologous to one another, and may originate from a single germline gene [1].
• Of 25 adults and 13 children responding to systemic immunization with Hib CP, only four and four, respectively, made K100 CP cross-reactive antibody, determined by radioantigen-binding inhibition [2].
• Cross-reactivity with Escherichia coli K100 in the human serum anticapsular antibody response to Haemophilus influenzae type B [2].
• Antibody to PRP that is cross-reactive with Escherichia coli K100 or Streptococcus pneumoniae type 6 capsular polysaccharides was detected in the secretions of seven and one subjects, respectively, but the amount was not correlated with serum cross-reactive antibody [3].
• Conjugates composed of Hib, Pn6A, or the cross-reacting Escherichia coli K100 covalently bound to tetanus toxoid (TT) were injected into young adult volunteers [4].

High impact information on C1QL3

• V region heterogeneity was examined by comparing cross-reactivity of anti-Hib-PS antibodies to the capsular polysaccharide of Escherichia coli K100 carbohydrate (K100 CHO) [5].
• The first type has no cross-reaction with K100 CHO and was found in 13 of the 14 individuals [5].
• In both the presence and absence of the Zn(2+) ion, the following residues on PC interact with cyt f: D44, D45, K6, D79, R93, and K100 that lie in a patch just below H92 and Y88 and D10, E17, and E70 located on the upper portion of the PC molecule [6].
• Virulence patterns and long-range genetic mapping of extraintestinal Escherichia coli K1, K5, and K100 isolates: use of pulsed-field gel electrophoresis [7].
• As an example, a placebo formulation containing 50% lactose 450Me, 22% Compritol((R)), 15% Precirol((R)), 8% sodium bicarbonate and 5% Methocel((R)) K100 (w/w) in the inner matrix, and 66% Precirol((R)) and 34% sodium bicarbonate (w/w) as a coating effervescent layer, showed very good floating capabilities [8].

Anatomical context of C1QL3

• Also the HPMC K100-based capsules spread better to the ascending colon than the HPMC K4M-based capsules [9].
• Most of the HPMC K100-based capsules were completely disintegrated during the 8h study, whereas the HPMC K4M-based capsules still exhibited plug formations in the large intestine [9].
• The gastrointestinal tracts of 12 were colonized with K1 E coli; 14 were colonized with K100 E coli; 12 control animals were not inoculated [10].

Associations of C1QL3 with chemical compounds

• The 3(2) full factorial design was employed to evaluate contribution of hydroxypropyl methyl cellulose (HPMC) K4M/HPMC K100 LV ratio (polymer blend) and sodium lauryl sulfate (SLS) on drug release from HPMC matrices [11].
• Floating tablets of famotidine were prepared employing two different grades of methocel K100 and methocel K15M by effervescent technique; these grades of methocel were evaluated for their gel forming properties [12].
• Two grades of HPMC (HPMC E5 and K100) as carriers were considered in order to prepare a sustained delivery system for theophylline which was used as a model drug [13].
• In Part 1, patients received saline (Group S), lidocaine (Group L), ketamine 10 mug/kg (Group K10), 50 mug/kg (Group K50), or 100 mug/kg (Group K100), respectively, immediately followed by propofol 2.5 mg/kg [14].

Analytical, diagnostic and therapeutic context of C1QL3

• Site-directed mutagenesis was then used to test whether amino acids P82, D83, E98, and K100 were important for the catalytic activity of MunI [15].
• Moreover, five patients with bacteriologically confirmed infections due to other pathogens (Streptococcus pneumoniae type 14 [two patients], Neisseria meningitidis group C, Escherichia coli K100, and Staphylococcus aureus) had false-positive LPA tests; only two (E. coli and S. aureus) were positive by ELISA [16].

References